Guangdong, Guangzhou, China
Founded in 2017, Mega Ophthalmology (HKEx stock code: 6622) is a leading ophthalmic pharmaceutical company dedicated to the research, development, production and commercialization of ophthalmic therapies to meet the huge global medical needs gap. Mega Ophthalmology was listed on the Main Board of the Hong Kong Stock Exchange on April 29, 2021.
Zhaoke Ophthalmology has established a pipeline of innovative and generic drugs covering six major ophthalmic indications affecting the anterior and posterior segments of the eye. Many of these drugs are currently manufactured in a state-of-the-art, fully operational production facility in Nansha, Guangzhou.
No key contacts have been added to this profile yet.
No reviews have been added to this profile yet.
This is the company profile page for Zhaoke Ophthalmology on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
